John M. Burke
Sarah Cannon(US)University of Colorado Cancer Center(US)Rocky Mountain Cancer Centers(US)University of Colorado Denver(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, HER2/EGFR in Cancer Research
Most-Cited Works
- → Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma(2021)723 cited
- → Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study(2014)626 cited
- → Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma(2017)417 cited
- → First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study(2019)295 cited
- → Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma(2012)275 cited
- → Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial